High-dose-rate interstitial brachytherapy for mobile tongue cancer: preliminary results of a dose reduction trial

PURPOSE: To compare the outcome of our facility with another about the shortened schedule (60 Gy in 10 fractions to 54 Gy in 9 fractions) of high-dose-rate interstitial brachytherapy (HDR ISBT) for mobile tongue cancer. MATERIAL AND METHODS: Eighteen patients were treated with HDR ISBT as a monother...

Descripción completa

Detalles Bibliográficos
Autores principales: Akiyama, Hironori, Yoshida, Ken, Yamazaki, Hideya, Takenaka, Tadashi, Kotsuma, Tadayuki, Masui, Koji, Yoshioka, Yasuo, Arika, Takumi, Shimizutani, Kimishige, Tanaka, Eiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003422/
https://www.ncbi.nlm.nih.gov/pubmed/24790616
http://dx.doi.org/10.5114/jcb.2014.40726
Descripción
Sumario:PURPOSE: To compare the outcome of our facility with another about the shortened schedule (60 Gy in 10 fractions to 54 Gy in 9 fractions) of high-dose-rate interstitial brachytherapy (HDR ISBT) for mobile tongue cancer. MATERIAL AND METHODS: Eighteen patients were treated with HDR ISBT as a monotherapy in dose reduction schedule with some unique technique to determine the border of tumor accuracy (lugol's staining and metal marker), and to minimize adverse effect (lead-lined silicon block) at our facility. RESULTS: The 2-year local and regional control rates and cause-specific survival rate were 82%, 80%, and 83% and moderate to severe late complications occurred in five patients (28%), which were almost the same treatment results achieved by another facility. CONCLUSIONS: We recommend 54 Gy in 9 fractions over 7 days as a feasible treatment to reduce patient discomfort in mobile tongue cancer patients.

Ejemplares similares